LLY

1,017.05

-2.37%↓

JNJ

244.37

+0.26%↑

ABBV

227.58

-2.48%↓

NVS

165.25

-0.83%↓

MRK

120.73

-0.93%↓

LLY

1,017.05

-2.37%↓

JNJ

244.37

+0.26%↑

ABBV

227.58

-2.48%↓

NVS

165.25

-0.83%↓

MRK

120.73

-0.93%↓

LLY

1,017.05

-2.37%↓

JNJ

244.37

+0.26%↑

ABBV

227.58

-2.48%↓

NVS

165.25

-0.83%↓

MRK

120.73

-0.93%↓

LLY

1,017.05

-2.37%↓

JNJ

244.37

+0.26%↑

ABBV

227.58

-2.48%↓

NVS

165.25

-0.83%↓

MRK

120.73

-0.93%↓

LLY

1,017.05

-2.37%↓

JNJ

244.37

+0.26%↑

ABBV

227.58

-2.48%↓

NVS

165.25

-0.83%↓

MRK

120.73

-0.93%↓

Inicio・Lista de Acciones・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Abierto

SectorSalud

35.08 -4.93

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

33.6

Máximo

37.5

Métricas clave
By Trading Economics
Ingresos	11M 51M
Ventas	39M 239M
P/B Media del Sector	11.36 110.024
BPA	1.08
Margen de beneficio	21.242
Empleados	268
EBITDA	14M 73M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+31.21% upside

Dividendos
By Dow Jones
Próximas Ganancias	24 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	387M 2.1B
Apertura anterior	40.01
Cierre anterior	35.08

Noticias sobre sentimiento de mercado

By Acuity

50%

165 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

29.8 / N/A Soporte y Resistencia

Harmony Biosciences Holdings Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

17 feb 2026, 23:44 UTC

Acciones populares

Stocks to Watch: La-Z-Boy, Palo Alto Networks, Caesars

17 feb 2026, 23:20 UTC

Ganancias

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps -- Update

17 feb 2026, 22:57 UTC

Ganancias

Santos Fiscal Year Net Profit Falls 33%, Nears Start of Alaska Project

17 feb 2026, 21:59 UTC

Ganancias

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps

17 feb 2026, 23:54 UTC

Charlas de Mercado

Nikkei May Rise as Fears About AI Disruption Ease -- Market Talk

17 feb 2026, 23:54 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

17 feb 2026, 23:54 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 feb 2026, 23:45 UTC

Charlas de Mercado

Suncorp's Outperformance of IAG Could Be Hard to Sustain -- Market Talk

17 feb 2026, 23:19 UTC

Ganancias

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17 feb 2026, 23:15 UTC

Ganancias

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17 feb 2026, 22:58 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Netflix Would Operate Warner's Studios, HBO Largely the Same -- Market Talk

17 feb 2026, 22:58 UTC

Adquisiciones, fusiones, absorciones

BlueScope Steel: Board Committed to Optimizing Value For Shareholders

17 feb 2026, 22:57 UTC

Adquisiciones, fusiones, absorciones

BlueScope Steel to Consider Revised SGH, Steel Dynamics Takeover Bid

17 feb 2026, 22:50 UTC

Adquisiciones, fusiones, absorciones

Agnico-Eagle Mines Acquired 662,780 Common Shrs of Maple Gold Mines at C$2.45 Per Common Shr >AEM.T

17 feb 2026, 22:44 UTC

Ganancias

Palo Alto Reports Strong Earnings. Its Stock Is Down. -- Barrons.com

17 feb 2026, 22:42 UTC

Ganancias

Santos FY Net Profit Falls 33%, Nears Start of Alaska Project

17 feb 2026, 22:36 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Netflix Sarandos: Paramount Causing Confusion Around Warner Deal -- Market Talk

17 feb 2026, 22:36 UTC

Ganancias

Santos Final Dividend 10.3 U.S. Cents/Security

17 feb 2026, 22:36 UTC

Ganancias

Santos FY Underlying Profit US$898 Million, Down 25%

17 feb 2026, 22:35 UTC

Ganancias

Santos FY Revenue US$4.94 Billion, Down 8%

17 feb 2026, 22:35 UTC

Ganancias

Correct: Santos FY Net Profit US$818 Million, Down 33%

17 feb 2026, 22:35 UTC

Adquisiciones, fusiones, absorciones

Berkshire Buys New York Times Stock; Sells Apple, Bank of America, Amazon In 4Q -- Barrons.com

17 feb 2026, 22:34 UTC

Ganancias

Santos FY Net Profit US$818 Billion, Down 33%

17 feb 2026, 22:02 UTC

Adquisiciones, fusiones, absorciones

Berkshire Pares Stakes in Apple and BofA, Adds New York Times Position -- Update

17 feb 2026, 21:50 UTC

Adquisiciones, fusiones, absorciones

Steel Dynamics: SGH Would Buy BlueScope, On-sell North American Operations to SDI, As Earlier Proposed

17 feb 2026, 21:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

17 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 feb 2026, 21:49 UTC

Adquisiciones, fusiones, absorciones

Steel Dynamics Says Revised Proposal Continues to Present Highly Strategic Opportunity For SDI Shareholders

17 feb 2026, 21:48 UTC

Adquisiciones, fusiones, absorciones

Steel Dynamics: BlueScope Offer a 56% Premium to 52-Week Volume Weighted Average Price

17 feb 2026, 21:48 UTC

Adquisiciones, fusiones, absorciones

Steel Dynamics: Consideration To Be Comprised Entirely of Cash

Comparación entre iguales

Cambio de precio

Harmony Biosciences Holdings Inc Esperado

Precio Objetivo

By TipRanks

31.21% repunte

Estimación a 12 meses

Media 47.25 USD 31.21%

Máximo 55 USD

Mínimo 42 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Harmony Biosciences Holdings Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Harmony Biosciences Holdings Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

29.8 / N/ASoporte y Resistencia

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

165 / 351 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.